Form 8-K - Current report:
SEC Accession No. 0001326732-24-000041
Filing Date
2024-08-05
Accepted
2024-08-05 16:06:01
Documents
15
Period of Report
2024-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xncr-20240805.htm   iXBRL 8-K 26231
2 EX-99.1 xncr-20240805xexx991.htm EX-99.1 76236
6 xncr-20221107xex99d1001.jpg GRAPHIC 8036
  Complete submission text file 0001326732-24-000041.txt   245735

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xncr-20240805.xsd EX-101.SCH 1898
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xncr-20240805_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xncr-20240805_pre.xml EX-101.PRE 12506
17 EXTRACTED XBRL INSTANCE DOCUMENT xncr-20240805_htm.xml XML 2728
Mailing Address 465 N. HALSTEAD ST. SUITE 200 PASADENA CA 91107
Business Address 465 N. HALSTEAD ST. SUITE 200 PASADENA CA 91107 626-305-5900
Xencor Inc (Filer) CIK: 0001326732 (see all company filings)

EIN.: 201622502 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36182 | Film No.: 241174747
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)